FDA panel gives nod to pulmonary hypertension drug

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

An FDA panel voted unanimously in favor of riociguat, an oral medication for two forms of pulmonary hypertension.

The Cardiovascular and Renal Drugs Advisory Committee reviewed the new drug application filed by Bayer HealthCare after the agency granted it priority review designation. Riociguat, (Adempas) is indicated as a treatment for pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). Members voted 11-0 to approve the drug for each indication.

Riociguat is an oral soluble guanylate cyclase stimulator designed to improve exercise capacity on PAH patients and patients with persistent/recurrent or inoperable CTEPH. Two Phase 3 trials showed a statistically significant improvement in the six-minute walk test after 16 and 12 weeks of treatment, according to Berlin-based Bayer.

The FDA usually, but not always, follows the recommendation of its advisory panels. 

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."